CSF somatostatin in affective illness and normal volunteers.
Somatostatin is a hypothalamic tetradecapeptide with many central nervous system actions. We investigated a potential role for altered somatostatin activity in affective disorder by measuring somatostatin in the cerebrospinal fluid (CSF) of 47 patients with affective disorder and of 39 normal volunteers. Medication-free depressed patients showed significantly lower levels of CSF somatostatin than normal volunteers (p less than .001) or patients during the improved state (p less than .01). Somatostatin levels were significantly and inversely correlated with duration of sleep on the night of the lumbar puncture (p less than .05). Treatment with carbamazepine reduced CSF somatostatin (p less than .01) in contrast to the absence of effect of imipramine, desmethylimipramine, and lithium carbonate and the significant increase in CSF somatostatin seen in a small group of patients treated with zimelidine. The implications of these findings with respect to attempts to explore the neurobiology of depression are discussed.
Rubinow
D R
DR
Gold
P W
PW
Post
R M
RM
Ballenger
J C
JC
D001714:Bipolar Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D002220:Carbamazepine / Q000627:therapeutic use; D003866:Depressive Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D003891:Desipramine / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D016651:Lithium Carbonate; D013004:Somatostatin / Q000134:cerebrospinal fluid*; D015031:Zimeldine / Q000627:therapeutic use
D016651:Lithium Carbonate; D002220:Carbamazepine; D015031:Zimeldine; D013004:Somatostatin; D008094:Lithium; D007099:Imipramine; D003891:Desipramine